search for




 

Original Article
Outcome of Hematopoietic Stem Cell Transplantation in Wiskott-Aldrich Syndrome
Clin Pediatr Hematol Oncol 2018;25:149-53.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Bo Kyung Kim, M.D., Kyung Taek Hong, M.D., Hyoung Jin Kang, M.D., Ph.D., Jung Yoon Choi, M.D., Hong Yul An, M.D. and Hee Young Shin, M.D.

Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul, Korea
Correspondence to: Hyoung Jin Kang
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, 101 Daehak-ro, Jongno-gu, Seoul 03722, Korea
Tel: +82-2-2072-3304
Fax: +82-2-743-3455
E-mail: kanghj@snu.ac.kr
ORCID ID: orcid.org/0000-0003-1009-6002
Received September 16, 2018; Revised September 24, 2018; Accepted October 6, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Wiskott-Aldrich syndrome (WAS) is a very rare disease and patients who do not receive timely treatment suffer from bleeding, infection, and malignancy. Hematopoietic stem cell transplantation (HSCT) has been recognized as an effective treatment, but the standard transplantation protocol has not been established. We report the outcomes of WAS patients who underwent HSCT in our institution.
Methods: We retrospectively studied patients who underwent HSCT at Seoul National University Children’s Hospital from 2005 to 2018. Busulfan-based myeloablative conditioning regimen was used, and an intensive daily therapeutic drug monitoring (TDM) for busulfan dosing was started for effective myeloablation and to reduce toxicity since 2008. We collected and analyzed data regarding symptoms, engraftment, transplantation-related toxicities, and survival.
Results: Six WAS patients who received HSCT were evaluated. The median age of the patients at diagnosis was 5 years (range, 1-11). There were 2 matched unrelated donor bone marrow transplantations, 3 matched unrelated peripheral blood stem cell transplantations (PBSCT), and 1 haploidentical PBSCT. No patient experienced engraftment failure. Three patients developed grades II to IV acute graft-versus-host disease (GVHD). Two patients had veno-occlusive disease (VOD). Two patients died (due to VOD and acute GVHD). The 5-year overall survival was 66.7% with 8 years of median follow-up. Particularly, a patient who underwent haploidentical PBSCT using targeted busulfan isalive with a follow-up duration of 3 years after HSCT.
Conclusion:In conclusion, WAS patients may be cured with HSCT with targeted busulfan-based myeloablative conditioning. But, long-term and multi-center studies are needed.
Keywords: Wiskott-Aldrich syndrome, Hematopoietic stem cell transplantation, Busulfan


October 2018, 25 (2)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Hyoung Jin Kang 

Funding Information